CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lowered its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 66.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,480 shares of the company’s stock after selling 22,648 shares during the period. Oppenheimer & Co. Inc.’s holdings in CRISPR Therapeutics were worth $452,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics in the 3rd quarter worth $40,000. Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics in the third quarter valued at about $43,000. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics in the fourth quarter worth about $39,000. Western Pacific Wealth Management LP lifted its holdings in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the period. Finally, Spire Wealth Management boosted its position in CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after buying an additional 1,482 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Up 5.1 %

Shares of NASDAQ CRSP opened at $45.53 on Friday. The firm has a market cap of $3.91 billion, a price-to-earnings ratio of -10.42 and a beta of 1.67. The company’s 50-day simple moving average is $42.79 and its 200-day simple moving average is $45.79. CRISPR Therapeutics AG has a 52-week low of $36.52 and a 52-week high of $81.73.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of recent research reports. Truist Financial raised their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Citigroup reduced their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a report on Tuesday, February 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Bank of America reduced their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average target price of $73.11.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Greene acquired 7,000 shares of the business’s stock in a transaction on Wednesday, February 26th. The stock was acquired at an average price of $44.85 per share, with a total value of $313,950.00. Following the acquisition, the director now owns 7,000 shares in the company, valued at $313,950. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 4.10% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.